7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/17/2013

Company Name Symbol %Change
VIASAT INC VSAT
19.35%
OLD SECOND B OSBC
5.76%
GAMCO INVEST GBL
4.61%
CORNING INC GLW
4.47%
SYNCHRONOSS SNCR
4.23%

Reiterate Allscripts at Neutral

by Zacks Equity Research

February 26, 2013 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Feb 21, we retained Allscripts Healthcare Solutions, Inc. ( MDRX - Analyst Report ) , a leading healthcare information technology (“HCIT”) solutions provider, at Neutral after the company missed the Zacks Consensus Estimates for revenues and earnings in fourth quarter 2012.

Why the Retention?

Allscripts posted fourth-quarter 2012 adjusted earnings of 8 cents per share, missing the Zacks Consensus Estimate of 17 cents per share. Revenues in the reported quarter dropped 9.6% year over year to $350.9 million, trailing the Zacks Consensus Estimate of $367 million. Bookings in the reported quarter were $180.7 million, a decrease of 44.8%.

Over the past month, the Zacks Consensus Estimate for 2013 has moved down by four cents to 63 cents while the same for 2014 has also dropped by four cents to 70 cents during the same timeframe.

The federal Stimulus program is gradually winding down. The results may be viewed in light of consolidation in an industry approaching maturity with a drop in greenfield opportunities but growth in the replacement market.

Allscripts has a prominent market share in both inpatient and ambulatory settings. Since incumbency is deemed to be the most significant competitive advantage, we believe the company will be a good performer in the long run.

In Dec 2012, the management of the company finished its evaluation of strategic alternatives. We view the absence of timely guidance as indicative of the uncertain ownership pattern of the company.

Cerner faces stiff competition from other established HCIT players, such as Athenahealth ( ATHN - Analyst Report ) , including low-cost cloud-based models.

Other Stocks to Consider

We currently have a Zacks Rank #4 (Sell) on Allscripts. However, we are more positive about other stocks such as Merge Healthcare Incorporated ( MRGE - Analyst Report ) and Becton, Dickinson and Company ( BDX - Analyst Report ) both of which carry a Zacks Rank #2 (Buy) and are expected to do well.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.